1<!DOCTYPE html> 2<html lang="en-GB"> 3 <head> 4 5 <!-- Google Tag Manager --> 6
6<script>
vendor: 368 bytes, lines 6-11
6 7 (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': 8 new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], 9 j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 10 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); 11 })(window,document,'script','dataLayer','
11GTM-P66K3L6
vendor: 10 bytes, lines 11-12
11'); 12
12</script>
12 13 <!-- End Google Tag Manager --> 14 15 <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> 16 <meta charset="utf-8"> 17 <title>News - Open Targets</title> 18 <meta name="description" content="Open Targets is a public-private initiative to generate evidence on the validity of therapeutic targets based on genome-scale experiments and analysis."> 19 <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css" integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm" crossorigin="anonymous"> 20 <link rel="stylesheet" href="/assets/css/main.css"> 21 <link rel="shortcut icon" href="/assets/img/favicons/open-targets-favicon.png" type="image/png" /> 22 <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css"> 23 </head> 24 <body> 25 26 <!-- Google Tag Manager (noscript) -->
vendor: 74 bytes, lines 26-27
26 27 <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
27GTM-P66K3L6
vendor: 102 bytes, lines 27-30
27" 28 height="0" width="0" style="display:none;visibility:hidden"></iframe> 29 </noscript> 30
30<!-- End Google Tag Manager (noscript) --> 31 32 <nav class="navbar navbar-expand-lg navbar-light bg-white"> 33 <div class="container"> 34 <a class="navbar-brand" href="/"> 35 <img src="/assets/img/ten-years-logo-colour.png" style="width:150px" alt="Ten year anniversary logo, Open Targets helix logo and wordmark"> 36 </a> 37 <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarResponsive" aria-controls="navbarResponsive" aria-expanded="false" aria-label="Toggle navigation"> 38 <span class="navbar-toggler-icon"></span> 39 </button> 40 <div class="collapse navbar-collapse" id="navbarResponsive"> 41 <ul class="navbar-nav ml-auto"> 42 <li class="nav-item dropdown"> 43 <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 44 About 45 </a> 46 <div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink"> 47 <a class="dropdown-item" href="/partners">Partners</a> 48 <a class="dropdown-item" href="/people">Team</a> 49 <a class="dropdown-item" href="/history">History</a> 50 <a class="dropdown-item" href="/branding">Branding</a> 51 </div> 52 </li> 53 <li class="nav-item dropdown"> 54 <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 55 Research 56 </a> 57 <div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink"> 58 <a class="dropdown-item" href="/science">Science overview</a> 59 <a class="dropdown-item" href="/publications">Publications</a> 60 </div> 61 </li> 62 <li class="nav-item"> 63 <a class="nav-link" href="/news">News</a> 64 </li> 65 <li class="nav-item"> 66 <a class="nav-link" href="/jobs">Jobs</a> 67 </li> 68 <li class="nav-item"> 69 <a class="nav-link" href="https://blog.opentargets.org/" target="_blank">Blog</a> 70 </li> 71 <li class="nav-item"> 72 <a class="nav-link" href="/contact">Contact</a> 73 </li> 74 </ul> 75 </div> 76 </div> 77</nav> 78 79 80 <header class="page-header bg-blue"> 81 <div class="container"> 82 <div class="row"> 83 <div class="col-sm-12 text-center text-white"> 84 <h1>News</h1> 85 </div> 86 </div> 87 </div> 88</header> 89 90<section class="py-5 my-5"> 91 <div class="container"> 92 <div class="row"> 93 94 95 <div class="row"> 96 <div class="col-lg-12"> 97 <div class="row"> 98 <div class="col-lg-6"> 99 100 <a href="/" target="_blank"> 101 <img src="/assets/img/masld-trajectory-july26.png" class="img-fluid" alt="Graphic highlighting the liver in the human body, overlayed with data from the publication showing the established human MASLD trajectory based on patient transcriptomic data."/> 102 </a> 103 104</div> 105<div class="col-lg-6"> 106 <h4>Molecular map of liver disease could transform how MASLD is diagnosed and monitored</h4> 107 <p class="mt-3"> 108 14 July 2026 109 </p> 110 <p> 111 <p><strong>A new study establishes a molecular map of disease progression in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), and identifies a set of blood biomarkers that could improve diagnosis.</strong></p> 112 113<h3 id="summary">Summary</h3> 114 115<ul> 116 <li>Scientists mapped the molecular progression of MASLD, uncovering how biological processes driving liver damage change over time, creating a framework for more precise stage-specific therapies.</li> 117 <li>They identified a blood... 118 </p> 119 120 <p class="card-title"> 121 <a href="/news/masld-trajectory-14-july-26.html" class="btn btn-primary">Read more</a> 122 </p> 123 124 125</div> 126 </div> 127 </div> 128 <div class="col-lg-12"> 129 <hr class="my-5" /> 130 </div> 131 </div> 132 133 <div class="row"> 134 <div class="col-lg-12"> 135 <div class="row"> 136 <div class="col-lg-6"> 137 138 <a href="/" target="_blank"> 139 <img src="/assets/img/krzak-ibdverse.png" class="img-fluid" alt="UMAP of the data from the project"/> 140 </a> 141 142</div> 143<div class="col-lg-6"> 144 <h4>Cellular study maps gene activity changes across more than 50 gut cell types in Crohnâs disease</h4> 145 <p class="mt-3"> 146 15 June 2026 147 </p> 148 <p> 149 <p>The latest IBDverse study identifies the genes expressed in Crohnâs disease, reveal
149ing a lasting âmolecular scarâ in the gut lining.</p> 150 151<p>A detailed cellular study of Crohnâs disease has mapped how gene activity changes across more than 50 cell types in the gut. The study provides an open resource of the genes that characterise each cell type and those whose activity shifts in disease, uncovering new molecular and cellular signatures of immune activity in the gut lining.</p> 152 153<p>Researc... 154 </p> 155 156 <p class="card-title"> 157 <a href="/news/ibdverse-krzak-june2026.html" class="btn btn-primary">Read more</a> 158 </p> 159 160 161</div> 162 </div> 163 </div> 164 <div class="col-lg-12"> 165 <hr class="my-5" /> 166 </div> 167 </div> 168 169 <div class="row"> 170 <div class="col-lg-12"> 171 <div class="row"> 172 <div class="col-lg-6"> 173 174 <a href="/" target="_blank"> 175 <img src="/assets/img/alegbeharris.png" class="img-fluid" alt="Graphic describing the project"/> 176 </a> 177 178</div> 179<div class="col-lg-6"> 180 <h4>Study of millions of cells reveals new way to understand genetic risk of disease</h4> 181 <p class="mt-3"> 182 3 June 2026 183 </p> 184 <p> 185 <p>Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.</p> 186 187<p>Published today (3 June) in Nature, the research carried out at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals NHS Foundation Trust (CUH), identifies the key genetic and cellular drivers of IBD risk and demonstrates the power of single-cell approaches to u... 188 </p> 189 190 <p class="card-title"> 191 <a href="/news/ibdverse-alegbeharris-june-2026.html" class="btn btn-primary">Read more</a> 192 </p> 193 194 195</div> 196 </div> 197 </div> 198 <div class="col-lg-12"> 199 <hr class="my-5" /> 200 </div> 201 </div> 202 203 <div class="row"> 204 <div class="col-lg-12"> 205 <div class="row"> 206 <div class="col-lg-6"> 207 208 <a href="https://www.sanger.ac.uk/news_item/immunotherapy-success-could-be-predicted-with-new-biomarkers//" target="_blank"> 209 <img src="/assets/img/cancer-biomarkers-watterson-jan26.png" class="img-fluid" alt="A tumoroid, colon cancer cells grown in 3D"/> 210 </a> 211 212</div> 213<div class="col-lg-6"> 214 <h4>Immunotherapy success could be predicted with new biomarkers</h4> 215 <p class="mt-3"> 216 20 January 2026 217 </p> 218 <p> 219 <p>The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumours respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most likely to benefit from treatment, new research shows.</p> 220 221<p>Researchers at the Wellcome Sanger Institute, Open Targets, Netherlands Cancer Institute and their collaborators used a powerful gene-editing tool called CRISPR in a novel approach that cultured tumour cells together with immune cells from the same in... 222 </p> 223 224 <p class="card-title"> 225 <a href="https://www.sanger.ac.uk/news_item/immunotherapy-success-could-be-predicted-with-new-biomarkers/" class="btn btn-primary" target="_blank">Read more</a> 226 </p> 227 228 229</div> 230 </div> 231 </div> 232 <div class="col-lg-12"> 233 <hr class="my-5" /> 234 </div> 235 </div> 236 237 <div class="row"> 238 <div class="col-lg-12"> 239 <div class="row"> 240 <div class="col-lg-6"> 241 242 <a href="https://www.ebi.ac.uk/about/news/announcements/new-data-initiative-launched-to-accelerate-discovery-and-personalised-care-for-mental-health-conditions//" target="_blank"> 243 <img src="/assets/img/OPP-funding-announcement.png" class="img-fluid" alt="Funding announcement"/> 244 </a> 245 246</div> 247<div class="col-lg-6"> 248 <h4>New data initiative accelerates discovery and personalised care for mental health conditions</h4> 249 <p class="mt-3"> 250 25 November 2025 251 </p> 252 <p> 253 <p>EMBL-EBI receives UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) funding for enhancing and translating mental-health omics data into the Open Targets Platform.</p> 254 255 </p> 256 257 <p class="card-title"> 258 <a href="https://www.ebi.ac.uk/about/news/announcements/new-data-initiative-launched-to-accelerate-discovery-and-personalised-care-for-mental-health-conditions/" class="btn btn-primary" target="_blank">Read more</a> 259 </p> 260 261 262</div> 263 </div> 264 </div> 265 <div class="col-lg-12"> 266 <hr class="my-5" /> 267 </div> 268 </div> 269 270 <div class="row"> 271 <div class="col-lg-12"> 272 <div class="row"> 273 <div class="col-lg-6"> 274 275 <a href="/" target="_blank"> 276 <img src="/assets/img/tumour_organoid_WellcomeSangerInstitute.png" class="img-fluid" alt="A tumoroid, colon cancer
276cells grown in 3D"/> 277 </a> 278 279</div> 280<div class="col-lg-6"> 281 <h4>Cancer drug resistance causes and categories identified</h4> 282 <p class="mt-3"> 283 18 October 2024 284 </p> 285 <p> 286 <p><strong>Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four main categories and highlighting possible new therapeutic targets.</strong></p> 287 288<p><br /></p> 289 290<p>All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.</p> 291 292<p>In a new large-scale study, re... 293 </p> 294 295 <p class="card-title"> 296 <a href="/news/cancer-drug-resistance-18-october-2024.html" class="btn btn-primary">Read more</a> 297 </p> 298 299 300</div> 301 </div> 302 </div> 303 <div class="col-lg-12"> 304 <hr class="my-5" /> 305 </div> 306 </div> 307 308 <div class="row"> 309 <div class="col-lg-12"> 310 <div class="row"> 311 <div class="col-lg-6"> 312 313 <a href="/" target="_blank"> 314 <img src="/assets/img/clinical-trial-stop-reasons-Jul24.png" class="img-fluid" alt="Graphic showing predicted trial stop reasons in rows with counts of trials per start year, clinical phase or therapeutic area shown by the color in each cell. The outcome groupings of the stopped reasons are shown using the color next to the stopped reason label."/> 315 </a> 316 317</div> 318<div class="col-lg-6"> 319 <h4>Why clinical trials stop: the role of genetics</h4> 320 <p class="mt-3"> 321 29 July 2024 322 </p> 323 <p> 324 <p><strong>Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.</strong></p> 325 326<p><br /></p> 327 328<p>Failure is the most likely outcome of a clinical trial. Learning from these failures by understanding which factors maximise the chances of a successful trial would help improve the drug discovery process. However, accessing information about failed clinical trials is difficult since the dr... 329 </p> 330 331 <p class="card-title"> 332 <a href="/news/clinical-trial-stop-reasons-Jul24.html" class="btn btn-primary">Read more</a> 333 </p> 334 335 336</div> 337 </div> 338 </div> 339 <div class="col-lg-12"> 340 <hr class="my-5" /> 341 </div> 342 </div> 343 344 <div class="row"> 345 <div class="col-lg-12"> 346 <div class="row"> 347 <div class="col-lg-6"> 348 349 <a href="/" target="_blank"> 350 <img src="/assets/img/vallier-liver-regeneration.png" class="img-fluid" alt="Liver hepatocytes"/> 351 </a> 352 353</div> 354<div class="col-lg-6"> 355 <h4>Researchers decipher mechanisms of liver regeneration</h4> 356 <p class="mt-3"> 357 23 May 2024 358 </p> 359 <p> 360 <p><strong>Scientists from the Berlin Institute of Health at Charité (BIH) and Open Targets together with colleagues from the University of Cambridge, and Addenbrookeâs Hospital in Cambridge, UK, uncovered mechanisms driving regeneration of the liver during chronic liver disease. This regenerative process allows the liver to repair itself when chronically injured but could also result in progression toward cancer. The researchers were able to demonstrate this first by performing single-cell a... 361 </p> 362 363 <p class="card-title"> 364 <a href="/news/mechanisms-of-liver-regeneration-vallier-may-2024.html" class="btn btn-primary">Read more</a> 365 </p> 366 367 368</div> 369 </div> 370 </div> 371 <div class="col-lg-12"> 372 <hr class="my-5" /> 373 </div> 374 </div> 375 376 <div class="row"> 377 <div class="col-lg-12"> 378 <div class="row"> 379 <div class="col-lg-6"> 380 381 <a href="/" target="_blank"> 382 <img src="/assets/img/openibd-press-release.png" class="img-fluid" alt="Open-IBD logo"/> 383 </a> 384 385</div> 386<div class="col-lg-6"> 387 <h4>Ambitious inflammatory bowel disease study aims to uncover disease biomarkers for personalised medicine</h4> 388 <p class="mt-3"> 389 17 May 2024 390 </p> 391 <p> 392 <p><strong>A unique study into IBD will bring together genomics and immunology experts, gastroenterologists, and patients from across the UK to i
392dentify new and personalised ways to predict, monitor, and treat Crohnâs disease and ulcerative colitis.</strong></p> 393 394<p>A new one-of-a-kind study into inflammatory bowel disease (IBD) is bringing together research institutions, hospitals, pharmaceutical partners, and patients to uncover what drives IBD onset and severity, identifying biomarkers to ... 395 </p> 396 397 <p class="card-title"> 398 <a href="/news/open-ibd-may-24.html" class="btn btn-primary">Read more</a> 399 </p> 400 401 402</div> 403 </div> 404 </div> 405 <div class="col-lg-12"> 406 <hr class="my-5" /> 407 </div> 408 </div> 409 410 <div class="row"> 411 <div class="col-lg-12"> 412 <div class="row"> 413 <div class="col-lg-6"> 414 415 <a href="/" target="_blank"> 416 <img src="/assets/img/msd-press-release.png" class="img-fluid" alt="MSD Logo"/> 417 </a> 418 419</div> 420<div class="col-lg-6"> 421 <h4>MSD joins the Open Targets consortium</h4> 422 <p class="mt-3"> 423 30 April 2024 424 </p> 425 <p> 426 <p>Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, today announced MSD, the tradename of Merck & Co., Inc., Rahway, N.J., USA, as the latest partner to join the consortium. Open Targets aims to accelerate the development of safe and effective medicines by leveraging cutting-edge technologies to identify, prioritise, and validate potential drug targets. MSDâs expertise in drug discovery will complement the strengths of the current partners: ... 427 </p> 428 429 <p class="card-title"> 430 <a href="/news/msd-joins-Open-Targets-Apr-2024.html" class="btn btn-primary">Read more</a> 431 </p> 432 433 434</div> 435 </div> 436 </div> 437 <div class="col-lg-12"> 438 <hr class="my-5" /> 439 </div> 440 </div> 441 442 <div class="row"> 443 <div class="col-lg-12"> 444 <div class="row"> 445 <div class="col-lg-6"> 446 447 <a href="https://www.sanger.ac.uk/news_item/new-screening-tool-to-explore-mechanisms-behind-cancer-autoimmunity-and-neurodegeneration//" target="_blank"> 448 <img src="/assets/img/scSNV-seq-Feb24-Greg-Moss.png" class="img-fluid" alt="A row of sequencing machines"/> 449 </a> 450 451</div> 452<div class="col-lg-6"> 453 <h4>New screening tool to explore mechanisms behind cancer, autoimmunity and neurodegeneration</h4> 454 <p class="mt-3"> 455 27 February 2024 456 </p> 457 <p> 458 <p>Mechanisms driving diseases such as cancer, autoimmunity, Alzheimerâs and Parkinsonâs could be uncovered using a new integrated single-cell approach to cellular genetic screening.</p> 459 460 </p> 461 462 <p class="card-title"> 463 <a href="https://www.sanger.ac.uk/news_item/new-screening-tool-to-explore-mechanisms-behind-cancer-autoimmunity-and-neurodegeneration/" class="btn btn-primary" target="_blank">Read more</a> 464 </p> 465 466 467</div> 468 </div> 469 </div> 470 <div class="col-lg-12"> 471 <hr class="my-5" /> 472 </div> 473 </div> 474 475 <div class="row"> 476 <div class="col-lg-12"> 477 <div class="row"> 478 <div class="col-lg-6"> 479 480 <a href="/" target="_blank"> 481 <img src="/assets/img/second-depmap-cover-nci.png" class="img-fluid" alt="Laboratory Researcher setting up genetic samples and primers for polymerase chain reaction."/> 482 </a> 483 484</div> 485<div class="col-lg-6"> 486 <h4>Cancer drug discovery accelerated as hundreds of overlooked targets prioritised</h4> 487 <p class="mt-3"> 488 11 January 2024 489 </p> 490 <p> 491 <p><i>The second generation of the Cancer Dependency Map uncovers 370 priority drug targets, with strong links to specific cancer types.</i></p> 492 493<p>A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.</p> 494 495<p>By looking at multiple layers of functional and genomic information, researchers were able to create an unbiased, panoramic view of what enables cancer cells to grow and survive. The... 496 </p> 497 498 <p class="card-title"> 499 <a href="/news/second-generation-depmap-11-january-2024.html" class="btn btn-primary">Read more</a> 500 </p> 501 502 503</div> 504 </div> 505 </div> 506 <div class="col-lg-12"> 507 <hr class="my-5" /> 508 </div> 509 </div> 510 511 <div class="row"> 512 <div class="col-lg-12"> 513 <div class="row"> 514 <div class="col-lg-6"> 515 516 <a href="/" target="_blank"> 517 <img src="/assets/img/HULCOOP_David_new_director_2023.png" class="img-fluid" alt="A man in a blue shirt is standing on the balcony of an office building made of metal and glass. He is posing and smiling at the camera, left hand in his pocket and right hand resting on the balcony railing. Surrounding trees can be seen in the background and reflected in the building."/> 518 </a> 519 520</div> 521<div class="col-lg-6"> 522 <h4>David Hulcoop appointed Open Targets Director</h4> 523 <p class="mt-3"> 524 5 July 2023
525 </p> 526 <p> 527 <p><i>July 5, Cambridge</i> â Open Targets has appointed David Hulcoop as its new Executive Director, following the retirement of Ian Dunham. Hulcoop will build from the programmeâs existing capabilities to maximise Open Targets impact on drug discovery decision making.</p> 528 529<p>Open Targets, a public-private partnership founded in 2014, aims to use the information generated by genome sequencing and genetics studies to systematically improve the identification and prioritisation of drug target... 530 </p> 531 532 <p class="card-title"> 533 <a href="/news/david-hulcoop-director-july-2023.html" class="btn btn-primary">Read more</a> 534 </p> 535 536 537</div> 538 </div> 539 </div> 540 <div class="col-lg-12"> 541 <hr class="my-5" /> 542 </div> 543 </div> 544 545 <div class="row"> 546 <div class="col-lg-12"> 547 <div class="row"> 548 <div class="col-lg-6"> 549 550 <a href="/" target="_blank"> 551 <img src="/assets/img/Pleiotropy_Karen_Arnott.png" class="img-fluid" alt="A stylized network of interconnected circles"/> 552 </a> 553 554</div> 555<div class="col-lg-6"> 556 <h4>Open Targets project creates a human interactome to prioritise drug discovery</h4> 557 <p class="mt-3"> 558 23 February 2023 559 </p> 560 <p> 561 <p>Scientists at Open Targets, EMBLâs European Bioinformatics Institute (EMBL-EBI), and GSK are revealing the shared basis of diseases using a map of interacting human proteins. By helping to understand how biological processes affect human traits and diseases, this work will prioritise new targets for drug discovery and identify drug repurposing opportunities.</p> 562 563<p>Proteins are molecules that do most of the work in our cells and are made following blueprints encoded in genes. They are ess... 564 </p> 565 566 <p class="card-title"> 567 <a href="/news/human-interactome-23-february-2023.html" class="btn btn-primary">Read more</a> 568 </p> 569 570 571</div> 572 </div> 573 </div> 574 <div class="col-lg-12"> 575 <hr class="my-5" /> 576 </div> 577 </div> 578 579 <div class="row"> 580 <div class="col-lg-12"> 581 <div class="row"> 582 <div class="col-lg-6"> 583 584 <a href="/" target="_blank"> 585 <img src="/assets/img/bowel-cancer-national-cancer-institute.png" class="img-fluid" alt="Human colorectal cancer cells stained purple, blue, and green under a microscope."/> 586 </a> 587 588</div> 589<div class="col-lg-6"> 590 <h4>Bowel cancer mutations that impact immunotherapy identified</h4> 591 <p class="mt-3"> 592 19 January 2023 593 </p> 594 <p> 595 <p><strong>Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the bodyâs immune response.</strong></p> 596 597<p>A new library documenting hundreds of mutations can help to explain why some cancers donât respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.</p> 598 599<p>The researchers, from the Wellcome Sanger Institute, Open Targets, and collaborators, used CRISPR gene editing technology and mini tumours... 600 </p> 601 602 <p class="card-title"> 603 <a href="/news/bowel-cancer-mutations-that-impact-immunotherapy-identified-19-january-2023.html" class="btn btn-primary">Read more</a> 604 </p> 605 606 607</div> 608 </div> 609 </div> 610 <div class="col-lg-12"> 611 <hr class="my-5" /> 612 </div> 613 </div> 614 615 <div class="row"> 616 <div class="col-lg-12"> 617 <div class="row"> 618 <div class="col-lg-6"> 619 620 <a href="/" target="_blank"> 621 <img src="/assets/img/OT_logo_400x800.png" class="img-fluid" alt="Open Targets logo"/> 622 </a> 623 624</div> 625<div class="col-lg-6"> 626 <h4>Open Targets consortium welcomes Genentech as newest member</h4> 627 <p class="mt-3"> 628 14 November 2022 629 </p> 630 <p> 631 <p>Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to
631join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBLâs European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.</p... 632 </p> 633 634 <p class="card-title"> 635 <a href="/news/genentech-joins-Open-Targets-Nov-2022.html" class="btn btn-primary">Read more</a> 636 </p> 637 638 639</div> 640 </div> 641 </div> 642 <div class="col-lg-12"> 643 <hr class="my-5" /> 644 </div> 645 </div> 646 647 <div class="row"> 648 <div class="col-lg-12"> 649 <div class="row"> 650 <div class="col-lg-6"> 651 652 <a href="/" target="_blank"> 653 <img src="/assets/img/soskic-cano-gamez-natgen-may22.png" class="img-fluid" alt="DNA spiral formed by pale blue dots on a dark background"/> 654 </a> 655 656</div> 657<div class="col-lg-6"> 658 <h4>Study tracking T-cell activation over time boosts search for immune disease treatments</h4> 659 <p class="mt-3"> 660 26 May 2022 661 </p> 662 <p> 663 <p>In a first-of-its-kind experiment, researchers have identified links between 127 genes and immune diseases, providing newfound insights into the sequence and timing of gene activity during the activation of T cells, a key process in regulating the bodyâs immune response.</p> 664 665<p>The study, led by researchers from Open Targets, the Wellcome Sanger Institute and GSK, is published today (26 May 2022) in Nature Genetics. The result of a 3 year research effort, it is the first to show that nume... 666 </p> 667 668 <p class="card-title"> 669 <a href="/news/T-cell-activation-dynamics-NatGen-May22.html" class="btn btn-primary">Read more</a> 670 </p> 671 672 673</div> 674 </div> 675 </div> 676 <div class="col-lg-12"> 677 <hr class="my-5" /> 678 </div> 679 </div> 680 681 <div class="row"> 682 <div class="col-lg-12"> 683 <div class="row"> 684 <div class="col-lg-6"> 685 686 <a href="/" target="_blank"> 687 <img src="/assets/img/Pfizer-press-release.png" class="img-fluid" alt="Pfizer logo on a white background"/> 688 </a> 689 690</div> 691<div class="col-lg-6"> 692 <h4>Pfizer joins the Open Targets consortium</h4> 693 <p class="mt-3"> 694 14 February 2022 695 </p> 696 <p> 697 <p>Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success rate for developing new medicines. This complements the strengths of the five current partners: EMBLâs European Bio... 698 </p> 699 700 <p class="card-title"> 701 <a href="/news/pfizer-press-release-Feb-2022.html" class="btn btn-primary">Read more</a> 702 </p> 703 704 705</div> 706 </div> 707 </div> 708 <div class="col-lg-12"> 709 <hr class="my-5" /> 710 </div> 711 </div> 712 713 <div class="row"> 714 <div class="col-lg-12"> 715 <div class="row"> 716 <div class="col-lg-6"> 717 718 <a href="https://www.nature.com/articles/s41588-021-00945-5/" target="_blank"> 719 <img src="/assets/img/l2g-pipeline-news-item.png" class="img-fluid" alt="Screenshot of steps involved in Open Targets Locus2Gene assignment pipeline"/> 720 </a> 721 722</div> 723<div class="col-lg-6"> 724 <h4>Locus-to-Gene method published in Nature Genetics</h4> 725 <p class="mt-3"> 726 28 October 2021 727 </p> 728 <p> 729 <p>Our locus-to-gene (L2G) machine learning scoring method was published in Nature Genetics (<a href="https://www.biorxiv.org/content/10.1101/2020.09.16.299271v2" target="_blank">the preprint is also available</a>). The L2G score reflects the likelihood that a gene is causal for the trait in question, allowing genes at trait-associated loci to be ranked by the relative strength of their evidence. It has been included in the Genetics portal since version 4.</p> 730 731 </p> 732 733 <p class="card-title"> 734 <a href="https://www.nature.com/articles/s41588-021-00945-5" class="btn btn-primary" target="_blank">Read more</a> 735 </p> 736 737 738</div> 739 </div> 740 </div> 741 <div class="col-lg-12"> 742 <hr class="my-5" /> 743 </div> 744 </div> 745 746 <div class="row"> 747 <div class="col-lg-12"> 748 <div class="row"> 749 <div class="col-lg-6"> 750 751 <a href="https://blog.opentargets.org/open-targets-genetics-version-5//" target="_blank"> 752 <img src="/assets/img/Genetics_Portal_v5_release_PheWAS_plot.png" class="img-fluid" alt="Screenshot of Open Targets Genetics PheWAS plot showing dropdown options"/> 753 </a> 754 755</div> 756<div class="col-lg-6"> 757 <h4>Open Targets releases new version of the Genetics Portal with FinnGen data</h4> 758 <p class="mt-3"> 759 30 June 2021 760 </p> 761 <p> 762 <p>
762In our latest <a href="https://genetics.opentargets.org/" target="_blank">Genetics Portal<a> release, we have <b>integrated over 2,700 study endpoints from FinnGen</b>, a public-private collaboration to identify genotype-phenotype correlations in the Finnish population. We have also <b>integrated over 11,800 new studies</b> from GWAS Catalog.</a></a></p> 763 764 </p> 765 766 <p class="card-title"> 767 <a href="https://blog.opentargets.org/open-targets-genetics-version-5/" class="btn btn-primary" target="_blank">Read more</a> 768 </p> 769 770 771</div> 772 </div> 773 </div> 774 <div class="col-lg-12"> 775 <hr class="my-5" /> 776 </div> 777 </div> 778 779 <div class="row"> 780 <div class="col-lg-12"> 781 <div class="row"> 782 <div class="col-lg-6"> 783 784 <a href="https://blog.opentargets.org/2020/07/29/covid-19-target-prioritisation-tool-released//" target="_blank"> 785 <img src="/assets/img/covid-19-portal-screenshot.png" class="img-fluid" alt="Screenshot of the Open Targets COVID19 Target Prioritisation tool showing a list of targets and key attributes for drug discovery"/> 786 </a> 787 788</div> 789<div class="col-lg-6"> 790 <h4>Open Targets releases a COVID-19 Target Prioritisation Tool</h4> 791 <p class="mt-3"> 792 29 July 2020 793 </p> 794 <p> 795 <p>Open Targets is excited to announce the release of our <a href="http://covid19.opentargets.org/" target="_blank">COVID-19 Target Prioritisation Tool</a>, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for 796<a href="https://platform.opentargets.org/disease/MONDO_0100096" target="_blank">COVID-19</a>.</p> 797 798 </p> 799 800 <p class="card-title"> 801 <a href="https://blog.opentargets.org/2020/07/29/covid-19-target-prioritisation-tool-released/" class="btn btn-primary" target="_blank">Read more</a> 802 </p> 803 804 805</div> 806 </div> 807 </div> 808 <div class="col-lg-12"> 809 <hr class="my-5" /> 810 </div> 811 </div> 812 813 <div class="row"> 814 <div class="col-lg-12"> 815 <div class="row"> 816 <div class="col-lg-6"> 817 818 <img src="/assets/img/open_targets_logo_news_item_placeholder.png" class="img-fluid" alt="Open Targets Helix logo and wordmark"/> 819 820</div> 821<div class="col-lg-6"> 822 <h4>Gosia Trynka awarded 2020 Leena Peltonen Prize</h4> 823 <p class="mt-3"> 824 6 June 2020 825 </p> 826 <p> 827 <p>Open Targets is excited to announce that <a href="https://www.sanger.ac.uk/person/trynka-gosia//">Gosia Trynka</a>, 828our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by 829the European Society for Human Genetics (ESHG).</p> 830 831<p>The prize is given every two years to an outstanding young researcher in the field of human genetics and it 832honours the memory of <a href="https://www.sanger.ac.uk/news_item/2010-03-11-professor-leena-peltonen-palotie-1952-2010/">Dr. ... 833 </p> 834 835 <p class="card-title"> 836 <a href="/assets/docs/Trynka_Peltonen_prize_announcement.pdf" class="btn btn-primary" target="_blank">Read more</a> 837 </p> 838 839 840</div> 841 </div> 842 </div> 843 <div class="col-lg-12"> 844 <hr class="my-5" /> 845 </div> 846 </div> 847 848 </div> 849 </div> 850</section> 851 852 <footer class="py-5 my-5 text-white" style="background-color: #5a5f5f"> 853 <div class="container text-center text-md-left"> 854 <div class="row"> 855 <div class="col-md-6 mt-md-0 mt-3"> 856 <h5 class="text-uppercase">Contact</h5> 857 <p> 858 To contact the Open Targets team, please email us at 859 <a class="text-white" href="mailto:[email protected]" 860 >[email protected]</a 861 > 862 </p> 863 <p><a class="text-white" href="https://www.ebi.ac.uk/data-protection/privacy-notice/embl-ebi-public-website/">Privacy Notice</a></p> 864 <h5 class="text-uppercase">Follow us</h5> 865 <ul class="list-unstyled list-inline"> 866 <li class="list-inline-item"> 867 <a 868 class="text-white" 869 href="https://www.linkedin.com/company/open-targets" 870 target="_blank" 871 > 872 <i class="fa fa-brands fa-2x fa-linkedin"></i> 873 </a> 874 </li> 875 <li class="list-inline-item"> 876 <a 877 class="text-white" 878 href="https://github.com/opentargets" 879 target="_blank" 880 > 881 <i class="fa-brands fa-2x fa-github"></i> 882 </a> 883 </li> 884 <li class="list-inline-item"> 885 <a 886 class="text-white" 887 href="https://bsky.app/profile/opentargets.org" 888 target="_blank" 889 > 890 <i class="fa fa-brands fa-2x fa-bluesky"></i> 891 </a> 892 </li> 893 <li class="list-inline-item"> 894 <a 895 class="text-white" 896 href="https://twitter.com/opentargets" 897 target="_blank" 898 > 899 <i class="fa fa-brands fa-2x fa-x-twitter"></i> 900 </a> 901 </li> 902 </ul> 903 <a href="https://www.netlify.com"> 904 <img 905 src="https://www.netlify.com/img/global/badges/netlify-light.svg" 906 alt="Deploys by Netlify" 907 /> 908 </a> 909 </div> 910 <!-- Grid column --> 911 912 <hr class="clearfix w-100 d-md-none pb-3" /> 913 914 <!-- Grid column --> 915 <div class="col-md-3 mb-md-0 mb-3"> 916 <!-- Links --> 917 <h5 class="text-uppercase">Partners</h5> 918 919 <ul class="list-unstyled"> 920 <li> 921 <a class="text-white" href="https://www.ebi.ac.uk/" target="_blank" 922 >
922European Bioinformatics Institute</a 923 > 924 </li> 925 <li> 926 <a class="text-white" href="https://www.gene.com/" target="_blank" 927 >Genentech</a 928 > 929 </li> 930 <li> 931 <a class="text-white" href="https://www.gsk.com/" target="_blank" 932 >GSK</a 933 > 934 </li> 935 <li> 936 <a class="text-white" href="https://www.msd.com/" target="_blank" 937 >MSD</a 938 > 939 </li> 940 <li> 941 <a class="text-white" href="https://www.pfizer.com/" target="_blank" 942 >Pfizer</a 943 > 944 </li> 945 <li> 946 <a class="text-white" href="https://www.sanofi.com/" target="_blank" 947 >Sanofi</a 948 > 949 </li> 950 <li> 951 <a 952 class="text-white" 953 href="https://www.sanger.ac.uk/" 954 target="_blank" 955 >Wellcome Sanger Institute</a 956 > 957 </li> 958 </ul> 959 </div> 960 <hr class="clearfix w-100 d-md-none pb-3" /> 961 <div class="col-md-3 mb-md-0 mb-3"> 962 <h5 class="text-uppercase">Open Targets</h5> 963 <ul class="list-unstyled"> 964 <li> 965 <a class="text-white" href="/science">Science</a> 966 </li> 967 <li> 968 <a class="text-white" href="/people">Team</a> 969 </li> 970 <li> 971 <a class="text-white" href="/publications">Publications</a> 972 </li> 973 <li> 974 <a class="text-white" href="/resources">Informatics tools</a> 975 </li> 976 <li> 977 <a class="text-white" href="/jobs">Jobs</a> 978 </li> 979 <li> 980 <a 981 class="text-white" 982 href="https://community.opentargets.org/" 983 target="_blank" 984 >Community</a 985 > 986 </li> 987 <li> 988 <a 989 class="text-white" 990 href="https://blog.opentargets.org/" 991 target="_blank" 992 >Blog</a 993 > 994 </li> 995 <li> 996 <a class="text-white" href="/contact">Contact</a> 997 </li> 998 </ul> 999 </div> 1000 </div> 1001 </div> 1002 1003 <div class="text-center py-3"> 1004 Copyright © 2017-2025 Open Targets. All rights reserved. 1005 </div> 1006</footer> 1007 1008
1008<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
1008 1009
1009<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script>
1009 1010
1010<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js" integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl" crossorigin="anonymous"></script>
1010 1011 1012 </body> 1013</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.